Huseyin Naci (M.H.S., Ph.D.) is an Associate Professor in the Department of Health Policy at the LSE. He conducts research and teaches on health care policy and practice in Europe and the US with a focus on pharmaceuticals. Huseyin serves as Co-Director of LSE’s Executive M.Sc. program in Health Economics, Outcomes and Management in Clinical Sciences. He is also one of the Deputy Directors of LSE Health.
Huseyin’s research evaluates the quantity and quality of the evidence base underpinning the approval, adoption, reimbursement, and use of new pharmaceutical products in Europe and the US. His recent work on pharmaceutical policy was funded by the Health Foundation. His research has appeared in leading medical and health policy journals, including JAMA, The Lancet, The BMJ, Health Affairs, and The Milbank Quarterly. His 2013 article comparing the mortality benefits of drug and non-drug interventions for common chronic conditions was selected as one of the “Five key BMJ research papers to mark the decade.” In 2020, Huseyin jointly led the development of the Lancet Series on Comparative Effectiveness, which identified the shortcomings of the current research landscape on new drugs both before and after approval, and outlined key changes to the regulatory system that would be required to ensure that patients, clinicians, and payers have timely access to the data they need for decision making.
Huseyin has a Ph.D. from the Department of Social Policy at the LSE and a Master’s in Health Sciences from the Johns Hopkins Bloomberg School of Public Health. He was previously a Fellow in Pharmaceutical Policy Research (2012-13) and a Pyle Fellow in Population Medicine (2013-14) at the Harvard Medical School and Harvard Pilgrim Health Care Institute. In 2018-19, he was the recipient of the UK Harkness Fellowship in Health Care Policy and Practice, based at the Harvard Kennedy School of Government. He was awarded LSE’s Excellence in Education Prize for “exceptional contributions to education” in 2020. Huseyin is a member of the UK National Institute for Health and Care Excellence (NICE) Medical Technologies Advisory Committee and serves as an Advisor to the Analysis section of The BMJ.
Programme Co-Director, Executive MSc in Health Economics, Outcomes and Management in Clinical Sciences
HP407 Evidence Review and Synthesis for Decision Making
HP433 Health Care Regulation
HP4C4E Systematic Review and Meta-analysis
HP500 Advanced Health Policy and Health Economics (MPhil/PhD course)
Program on Regulation, Therapeutics and Law (PORTAL), Harvard Medical School (https://www.portalresearch.org)
Meta-Research Innovation Center at Stanford (METRICS) (https://metrics.stanford.edu)